71
Views
7
CrossRef citations to date
0
Altmetric
Review

Disparity implications of the Medicare medication therapy management eligibility criteria: a literature review

, , , , &
Pages 201-216 | Published online: 09 Jan 2014

References

  • Koh HK, Graham G, Glied SA. Reducing racial and ethnic disparities: the action plan from the department of health and human services. Health Aff. (Millwood) 30(10), 1822–1829 (2011).
  • Mayberry RM, Mili F, Ofili E. Racial and ethnic differences in access to medical care. Med. Care Res. Rev. 57(Suppl. 1), 108–145 (2000).
  • Weinick RM, Zuvekas SH, Cohen JW. Racial and ethnic differences in access to and use of health care services, 1977 to 1996. Med. Care Res. Rev. 57(Suppl. 1), 36–54 (2000).
  • Smedley BD, Stith AY, Nelson AR. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. National Academies Press, Washington, DC, USA (2002).
  • Koh HK. A 2020 vision for healthy people. N. Engl. J. Med. 362(18), 1653–1656 (2010).
  • Jones CP. Levels of racism: a theoretic framework and a gardener’s tale. Am. J. Public Health 90(8), 1212–1215 (2000).
  • Centers for Medicare and Medicaid Services; Department of Health and Human Services. Medicare program; Medicare prescription drug benefit. Final rule. Fed. Regist. 70(18), 4193–4585 (2005).
  • Bluml BM. Definition of medication therapy management: development of professionwide consensus. J. Am. Pharm. Assoc. (2003) 45(5), 566–572 (2005).
  • American Pharmacists Association and National Association of Chain Drug Stores Foundation. Medication therapy management in community pharmacy practice: core elements of an MTM service (version 1.0). J. Am. Pharm. Assoc. 45(5), 573–579 (2005).
  • Cranor CW, Christensen DB. The Asheville Project: short-term outcomes of a community pharmacy diabetes care program. J. Am. Pharm. Assoc. (Wash.) 43(2), 149–159 (2003).
  • Cranor CW, Bunting BA, Christensen DB. The Asheville Project: long-term clinical and economic outcomes of a community pharmacy diabetes care program. J. Am. Pharm. Assoc. (Wash.) 43(2), 173–184 (2003).
  • Bunting BA, Smith BH, Sutherland SE. The Asheville Project: clinical and economic outcomes of a community-based long-term medication therapy management program for hypertension and dyslipidemia. J. Am. Pharm. Assoc. (2003) 48(1), 23–31 (2008).
  • Fera T, Bluml BM, Ellis WM. Diabetes Ten City Challenge: final economic and clinical results. J. Am. Pharm. Assoc. (2003) 49(3), 383–391 (2009).
  • Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch. Intern. Med. 162(20), 2269–2276 (2002).
  • Thorpe KE, Ogden LL, Galactionova K. Chronic conditions account for rise in Medicare spending from 1987 to 2006. Health Aff. (Millwood) 29(4), 718–724 (2010).
  • Wang J, Mullins CD, Brown LM et al. Disparity implications of Medicare eligibility criteria for medication therapy management services. Health Serv. Res. 45(4), 1061–1082 (2010).
  • Exworthy M, Bindman A, Davies H, Washington AE. Evidence into policy and practice? Measuring the progress of U.S. and U.K. policies to tackle disparities and inequalities in U.S. and U.K. health and health care. Milbank Q. 84(1), 75–109 (2006).
  • Schommer JC, Planas LG, Johnson KA, Doucette WR. Pharmacist-provided medication therapy management (part 2): payer perspectives in 2007. J. Am. Pharm. Assoc. (2003) 48(4), 478–486 (2008).
  • Briesacher B, Limcangco R, Gaskin D. Racial and ethnic disparities in prescription coverage and medication use. Health Care Financ. Rev. 25(2), 63–76 (2003).
  • Gaskin DJ, Briesacher BA, Limcangco R, Brigantti BL. Exploring racial and ethnic disparities in prescription drug spending and use among Medicare beneficiaries. Am. J. Geriatr. Pharmacother. 4(2), 96–111 (2006).
  • Phillips VL, Atherly A. Prescription drug costs for dually eligible people in a Medicaid home- and community-based services program. J. Am. Geriatr. Soc. 50(7), 1283–1288 (2002).
  • Schore J, Brown R, Lavin B. Racial disparities in prescription drug use among dually eligible beneficiaries. Health Care Financ. Rev. 25(2), 77–90 (2003).
  • Schneider EC, Zaslavsky AM, Epstein AM. Racial disparities in the quality of care for enrollees in Medicare managed care. JAMA 287(10), 1288–1294 (2002).
  • Zuckerman IH, Ryder PT, Simoni-Wastila L et al. Racial and ethnic disparities in the treatment of dementia among Medicare beneficiaries. J. Gerontol. B. Psychol. Sci. Soc. Sci. 63(5), S328–S333 (2008).
  • Poon I, Lal LS, Ford ME, Braun UK. Racial/ethnic disparities in medication use among veterans with hypertension and dementia: a national cohort study. Ann. Pharmacother. 43(2), 185–193 (2009).
  • Gornick ME, Eggers PW, Reilly TW et al. Effects of race and income on mortality and use of services among Medicare beneficiaries. N. Engl. J. Med. 335(11), 791–799 (1996).
  • Gornick ME. Disparities in Medicare services: potential causes, plausible explanations, and recommendations. Health Care Financ. Rev. 21(4), 23–43 (2000).
  • McGinnis KA, Fine MJ, Sharma RK et al.; Veterans Aging Cohort 3-Site Study (VACS 3). Understanding racial disparities in HIV using data from the veterans aging cohort 3-site study and VA administrative data. Am. J. Public Health 93(10), 1728–1733 (2003).
  • Newsome BB, McClellan WM, Allison JJ et al. Racial differences in the competing risks of mortality and ESRD after acute myocardial infarction. Am. J. Kidney Dis. 52(2), 251–261 (2008).
  • Ciol MA, Shumway-Cook A, Hoffman JM, Yorkston KM, Dudgeon BJ, Chan L. Minority disparities in disability between Medicare beneficiaries. J. Am. Geriatr. Soc. 56(3), 444–453 (2008).
  • Whitson HE, Hastings SN, Landerman LR, Fillenbaum GG, Cohen HJ, Johnson KS. Black–white disparity in disability: the role of medical conditions. J. Am. Geriatr. Soc. 59(5), 844–850 (2011).
  • Kotzan L, Carroll NV, Kotzan JA. Influence of age, sex, and race on prescription drug use among Georgia Medicaid recipients. Am. J. Hosp. Pharm. 46(2), 287–290 (1989).
  • Khandker RK, Simoni-Wastila LJ. Differences in prescription drug utilization and expenditures between blacks and whites in the Georgia Medicaid population. Inquiry 35(1), 78–87 (1998).
  • Zito JM, Safer DJ, Zuckerman IH, Gardner JF, Soeken K. Effect of Medicaid eligibility category on racial disparities in the use of psychotropic medications among youths. Psychiatr. Serv. 56(2), 157–163 (2005).
  • Depp C, Ojeda VD, Mastin W, Unützer J, Gilmer TP. Trends in use of antipsychotics and mood stabilizers among Medicaid beneficiaries with bipolar disorder, 2001–2004. Psychiatr. Serv. 59(10), 1169–1174 (2008).
  • Horvitz-Lennon M, McGuire TG, Alegria M, Frank RG. Racial and ethnic disparities in the treatment of a Medicaid population with schizophrenia. Health Serv. Res. 44(6), 2106–2122 (2009).
  • Crystal S, Sambamoorthi U, Moynihan PJ, McSpiritt E. Initiation and continuation of newer antiretroviral treatments among Medicaid recipients with AIDS. J. Gen. Intern. Med. 16(12), 850–859 (2001).
  • King WD, Minor P, Ramirez KC et al. Racial, gender and geographic disparities of antiretroviral treatment among US Medicaid enrollees in 1998. J. Epidemiol. Community Health 62(9), 798–803 (2008).
  • Lieu TA, Lozano P, Finkelstein JA et al. Racial/ethnic variation in asthma status and management practices among children in managed Medicaid. Pediatrics 109(5), 857–865 (2002).
  • Shaya FT, Blume S. Prescriptions for cyclooxygenase-2 inhibitors and other nonsteroidal anti-inflammatory agents in a Medicaid managed care population: African Americans versus Caucasians. Pain Med. 6(1), 11–17 (2005).
  • Litaker D, Koroukian S, Frolkis JP, Aron DC. Disparities among the disadvantaged: variation in lipid management in the Ohio Medicaid program. Prev. Med. 42(4), 313–315 (2006).
  • Chen AY, Chang RK. Factors associated with prescription drug expenditures among children: an analysis of the Medical Expenditure Panel survey. Pediatrics 109(5), 728–732 (2002).
  • Wang J, Noel JM, Zuckerman IH, Miller NA, Shaya FT, Mullins CD. Disparities in access to essential new prescription drugs between non-Hispanic whites, non-Hispanic blacks, and Hispanic whites. Med. Care Res. Rev. 63(6), 742–763 (2006).
  • Wang J, Zuckerman IH, Miller NA, Shaya FT, Noel JM, Mullins CD. Utilizing new prescription drugs: disparities among non-Hispanic whites, non-Hispanic blacks, and Hispanic whites. Health Serv. Res. 42(4), 1499–1519 (2007).
  • Chen J, Fang H, Vargas-Bustamante A, Rizzo JA, Ortega AN. Latino disparities in prescription drug use and expenditures: a nationally representative analysis. Ann. Pharmacother. 44(1), 57–69 (2010).
  • Smith SR, Kirking DM. Access and use of medications in HIV disease. Health Serv. Res. 34(1 Pt 1), 123–144 (1999).
  • Gebo KA, Fleishman JA, Conviser R et al.; HIV Research Network. Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J. Acquir. Immune Defic. Syndr. 38(1), 96–103 (2005).
  • Han E, Liu GG. Racial disparities in prescription drug use for mental illness among population in US. J. Ment. Health Policy Econ. 8(3), 131–143 (2005).
  • Wang J, White-Means SI, Hufstader MA, Walker GD. The economic implications of the racial and ethnic disparities in the use of selective serotonin reuptake inhibitors. Curr. Med. Res. Opin. 23(4), 853–863 (2007).
  • González HM, Croghan T, West B et al. Antidepressant use in black and white populations in the United States. Psychiatr. Serv. 59(10), 1131–1138 (2008).
  • Winters KP, Wyatt SB, Nick TG, Hewlett PO, Hyde JC, Fletcher AB. Race, stability of health insurance coverage, and prescription medication use. ABNF J. 21(1), 21–26 (2010).
  • Brancati FL, Kao WH, Folsom AR, Watson RL, Szklo M. Incident Type 2 diabetes mellitus in African American and white adults: the Atherosclerosis Risk in Communities Study. JAMA 283(17), 2253–2259 (2000).
  • Kramer H, Han C, Post W et al. Racial/ethnic differences in hypertension and hypertension treatment and control in the multi-ethnic study of atherosclerosis (MESA). Am. J. Hypertens. 17(10), 963–970 (2004).
  • Hoffman RM, Gilliland FD, Eley JW et al. Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J. Natl Cancer Inst. 93(5), 388–395 (2001).
  • Li CI, Malone KE, Daling JR. Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch. Intern. Med. 163(1), 49–56 (2003).
  • Hayes DK, Greenlund KJ, Denny CH, Neyer JR, Croft JB, Keenan NL. Racial/ethnic and socioeconomic disparities in health-related quality of life among people with coronary heart disease, 2007. Prev. Chronic Dis. 8(4), A78 (2011).
  • Carpenter DM, Schoster B, Shreffler JH, Callahan LF. Racial/ethnic differences in quality of life for people living with arthritis who see a primary care physician. Open Rheumatol. J. 5, 24–29 (2011).
  • Krieger N. Refiguring ‘race’: epidemiology, racialized biology, and biological expressions of race relations. Int. J. Health Serv. 30(1), 211–216 (2000).
  • Laws MB. Race and ethnicity in biomedical and health services research. Arch. Pediatr. Adolesc. Med. 155(8), 972–973; author reply 973 (2001).
  • Karter AJ. Race and ethnicity: vital constructs for diabetes research. Diabetes Care 26(7), 2189–2193 (2003).
  • Bhopal R. Is research into ethnicity and health racist, unsound, or important science? BMJ 314(7096), 1751–1756 (1997).
  • LaVeist TA, Gaskin D, Richard P. Estimating the economic burden of racial health inequalities in the United States. Int. J. Health Serv. 41(2), 231–238 (2011).
  • Fishman J, O’Dwyer P, Lu HL, Henderson H, Asch DA, Casarett DJ. Race, treatment preferences, and hospice enrollment: eligibility criteria may exclude patients with the greatest needs for care. Cancer 115(3), 689–697 (2009).
  • Chen J, Rizzo JA, Ortega AN. Racial and ethnic differences in drug expenditures and access under Medicare Part D. J. Health Care Poor Underserved 22(3), 1059–1074 (2011).
  • McKenney NR, Bennett CE. Issues regarding data on race and ethnicity: the Census Bureau experience. Public Health Rep. 109(1), 16–25 (1994).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.